- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.03. | Portage Biotech Inc.: Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares | 1 | GlobeNewswire (USA) | ||
| 14.03. | Intensity Therapeutics GAAP EPS of -$1.38 | 4 | Seeking Alpha | ||
| 14.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update | 71 | PR Newswire | INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancer
Year-end cash and investments of $14.8 million expected to fund operations through... ► Artikel lesen | |
| 14.03. | INTENSITY THERAPEUTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 07.02. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 03.01. | Intensity Therapeutics To Initiate Phase 3 Sarcoma Trial In H1 | 3 | RTTNews | ||
| 03.01. | Intensity Therapeutics Inc.: Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program | 279 | PR Newswire | FDA provides "Study May Proceed" letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024
SHELTON, Conn., Jan. 3, 2024... ► Artikel lesen | |
| 12.12.23 | Intensity Therapeutics appoints Joseph Talamo as its CFO | 2 | Seeking Alpha | ||
| 12.12.23 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.12.23 | Why Is Intensity Therapeutics (INTS) Stock Up 133% Today? | 2 | InvestorPlace | ||
| 08.12.23 | Intensity Therapeutics rises on positive breast-cancer study data | 6 | Reuters | ||
| 08.12.23 | Why Is Cancer Focused Intensity Therapeutics Stock Trading Over 100% Today? | 5 | Benzinga.com | ||
| 22.11.23 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.11.23 | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.11.23 | Intensity Therapeutics GAAP EPS of -$0.17 misses by $0.08 | 2 | Seeking Alpha | ||
| 13.11.23 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.23 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update | 327 | PR Newswire | Presented positive Phase 1/2 clinical data for INT230-6 in patients with refractory soft tissue sarcoma at Connective Tissue Oncology Society ("CTOS"), demonstrating 93% disease control rate in patients... ► Artikel lesen | |
| 14.08.23 | Intensity Therapeutics, Inc.: Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update | 188 | PR Newswire | Closed Upsized IPO Priced at Top-Of-Range, Full Exercise of the Over-Allotment Nets $20.4 Million in Proceeds
Data Presented at ASCO Showed that Lead Asset INT230-6 Prolongs Survival Alone or in Combination... ► Artikel lesen | |
| 30.06.23 | Intensity Therapeutics Prices Upsized IPO Of 3.90 Mln Shares At $5.00/shr | 687 | AFX News | WASHINGTON (dpa-AFX) - Intensity Therapeutics Inc. (INTS) said that it has priced its upsized initial public offering of 3.90 million shares of common stock at a public offering price of $5.00... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,80 | +1,37 % | Große Unruhe im BioTech-Sektor! Evotec und Medigene vor Ausbruch, Bayer und BioNTech stottern! | Der DAX 40-Index hat in 2024 bereits einen großen Lauf hinter sich gebracht. Getrieben von den Hightech-Werten der NASDAQ konnte Anfang April ein Hoch von 18.567 Punkten erreicht werden. Die ehemaligen... ► Artikel lesen | |
| NOVAVAX | 4,237 | +4,30 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| CRISPR THERAPEUTICS | 50,35 | +1,61 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.03.2024 - 4 | The following instruments on Boerse Frankfurt do have their last trading day on 14.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.03.2024ISIN NameCH0305285295 VARIA... ► Artikel lesen | |
| EDITAS MEDICINE | 5,230 | +7,24 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates | Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,842 | 0,00 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| ADAPTIMMUNE THERAPEUTICS | 1,110 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 | Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell... ► Artikel lesen | |
| ADVERUM BIOTECHNOLOGIES | 9,000 | +2,51 % | Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy | ||
| SPRINGWORKS THERAPEUTICS | 46,840 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN | STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced... ► Artikel lesen | |
| MORPHOSYS | 65,95 | -0,38 % | EQS-PVR: MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: MorphoSys AG
MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
25.04.2024 / 16:00 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ARVINAS | 32,480 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,740 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,310 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| EVOTEC | 9,900 | +1,64 % | Allianz, Andritz, CureVac, Deutsche Telekom, Evotec - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| COGENT BIOSCIENCES | 6,910 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor | WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 28,100 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen |
Das Unternehmen INTENSITY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
